January 24, 2025 Takeda-backed Ascentage Pharma aims to raise ... gets US approval Ascendis Pharma said on Monday the U.S. Food & Drug Administration had approved its therapy to treat adult ...
Takeda’s (NYSE: TAK) (TSE:4502) plasma-derived therapies (PDT) business, led by Giles Platford, president of Takeda’s Plasma-Derived Therapies Business Unit and chair of the Plasma Protein ...
On Monday, Protagonist Therapeutics, Inc. (NASDAQ:PTGX) and Takeda Pharmaceutical Co Ltd (NYSE:TAK) released topline results for the Phase 3 VERIFY study of rusfertide for polycythemia vera.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback